Painful diabetic neuropathy can cause burning, tingling, electric-shock pain, numbness, sleep disruption, and difficulty walking. Medications and careful diabetes management help many people, but some patients continue to have disabling symptoms despite appropriate treatment. For carefully selected patients, spinal cord stimulation (SCS) may offer another option.
What does the strongest evidence show?
A multicenter randomized clinical trial involving 216 patients compared conventional medical management alone with conventional care plus 10-kHz spinal cord stimulation. At the three-month primary endpoint, 79% of patients assigned to 10-kHz SCS met the study’s composite response endpoint, compared with 5% of patients receiving conventional medical management alone.
Long-term follow-up also found durable benefit among implanted patients. At 24 months, average pain reduction was approximately 80%, and about 90% of participants achieved at least 50% pain relief. These results are encouraging, but they apply to carefully screened patients with painful diabetic neuropathy that remained inadequately controlled despite medical treatment.
Can SCS improve sensation or nerve health?
This is an important and evolving research question. A small 2023 prospective pilot study enrolled eight patients; six completed 12-month follow-up. Investigators reported pain relief, improvement in sensory testing, and increases in skin and corneal nerve-fiber measurements. Because the study was small, open-label, and did not include a control group, it does not prove that SCS regenerates damaged nerves.
A larger randomized, sham-controlled study called PDN-Sensory has been designed to evaluate pain, protective sensation, neurological function, and objective nerve-fiber measures. Until results are available, claims that spinal cord stimulation restores or regenerates peripheral nerves should be considered preliminary.
How does spinal cord stimulation work?
SCS uses thin leads placed in the epidural space and a small implanted pulse generator to deliver electrical signals that modify pain processing. Treatment usually begins with a temporary trial. A permanent system is considered only when the trial provides meaningful benefit and the patient remains an appropriate candidate.
Who may be a candidate?
Evaluation may be reasonable for adults who have:
• Painful diabetic peripheral neuropathy that significantly affects function or sleep
• Inadequate relief from appropriate medications and conservative care
• Diabetes and other medical conditions controlled well enough for an elective procedure
• No untreated infection or other major contraindication
• Realistic expectations and the ability to participate in follow-up and device programming
Potential benefits and risks
Possible benefits include meaningful pain reduction, better sleep, improved function, and improved quality of life. Risks can include infection, bleeding, lead migration, device discomfort or malfunction, inadequate relief, and the need for revision or removal. Outcomes vary, and SCS does not replace diabetes management, foot care, or treatment of other causes of neuropathy.
A careful, individualized evaluation matters
At Texas Pain and Regenerative Medicine, Samir Fahed, MD, evaluates each patient’s diagnosis, prior treatments, medical risks, functional goals, and expectations before discussing neuromodulation. When appropriate, a temporary SCS trial can help determine whether the therapy is likely to provide meaningful benefit before permanent implantation.
To request an evaluation, call 832-486-9346. Our office is located at 11226 Southwest Freeway, Suite A, Houston, TX 77031.
This article is for general educational purposes and is not a substitute for individualized medical advice.
Selected research
Petersen EA, et al. Effect of High-frequency (10-kHz) Spinal Cord Stimulation in Patients With Painful Diabetic Neuropathy: A Randomized Clinical Trial. JAMA Neurology. 2021;78(6):687-698.
Petersen EA, et al. Long-term efficacy of high-frequency (10 kHz) spinal cord stimulation for the treatment of painful diabetic neuropathy: 24-month results of a randomized controlled trial. Diabetes Research and Clinical Practice. 2023;203:110865.
Chen J, et al. High-frequency spinal cord stimulation (10 kHz) alters sensory function and nerve fiber density in painful diabetic neuropathy: a pilot prospective open-label study. Pain Medicine. 2023;24(Suppl 2):S33-S40.
Pop-Busui R, et al. Evaluating pain and neurological function with high-frequency 10 kHz spinal cord stimulation in painful diabetic neuropathy: design of the multicentre, randomised, sham-controlled PDN-Sensory study. BMJ Open. 2025.
